Cevostamab Validates FcRH5 in Late-Line Myeloma

Company Roche / Genentech Event Type Peer-Reviewed Publication (Phase 1 Full Dataset) Modality Bispecific T-Cell Engager (FcRH5 x CD3) Asset Cevostamab Target FcRH5 (FCRL5) / CD3 Disease Area Relapsed or Refractory Multiple Myeloma Summary A full peer-reviewed analysis of Roche and Genentech’s cevostamab phase 1…